Cue Biopharma (CUE) Stock Forecast, Price Target & Predictions
CUE Stock Forecast
Cue Biopharma stock forecast is as follows: an average price target of $4.33 (represents a 293.64% upside from CUE’s last price of $1.10) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CUE Price Target
The average price target for Cue Biopharma (CUE) is $4.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $2.00. This represents a potential 293.64% upside from CUE's last price of $1.10.
CUE Analyst Ratings
According to 3 Wall Street analysts, Cue Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for CUE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cue Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Maury Raycroft | Jefferies | $4.00 | $1.28 | 211.28% | 263.64% |
| Jul 26, 2024 | Reni Benjamin | JMP Securities | $2.00 | $0.70 | 184.37% | 81.82% |
| Mar 13, 2024 | Maury Raycroft | Jefferies | $6.00 | $2.15 | 179.07% | 445.45% |
| Nov 20, 2022 | Edward Tenthoff | Piper Sandler | $7.00 | $3.22 | 117.39% | 536.36% |
The latest Cue Biopharma stock forecast, released on Nov 15, 2024 by Maury Raycroft from Jefferies, set a price target of $4.00, which represents a 211.28% increase from the stock price at the time of the forecast ($1.28), and a 263.64% increase from CUE last price ($1.10).
Cue Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $4.00 | $4.00 | $4.00 |
| Last Closing Price | $1.10 | $1.10 | $1.10 |
| Upside/Downside | 263.64% | 263.64% | 263.64% |
In the current month, the average price target of Cue Biopharma stock is $4.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 263.64% increase as opposed to Cue Biopharma's last price of $1.10. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 26, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Apr 09, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Apr 09, 2024 | Piper Sandler | Buy | Buy | Hold |
| Nov 20, 2022 | Piper Sandler | - | Overweight | Initialise |
Cue Biopharma's last stock rating was published by Jefferies on Nov 15, 2024. The company gave CUE a "Buy" rating, the same as its previous rate.
Cue Biopharma Financial Forecast
Cue Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $1.38M | $187.00K | $151.23K | $68.00K | $26.00K | $1.00M | $1.57M | $2.40M | $2.74M | $1.55M | $475.32K | $704.00K | $1.07M | $900.00K | $1.05M | $984.00K | $1.05M | $370.00K | $449.00K |
| Avg Forecast | $1.20M | $1.13M | $1.10M | $766.67K | $1.43M | $1.52M | $1.29M | $1.21M | $966.67K | $1.31M | $907.50K | $1.95M | $103.75K | $513.50K | $1.13M | $3.05M | $1.14M | $2.40M | $1.06M | $585.60K | $1.49M | $1.27M | $930.00K | $1.36M | $836.00K | $225.00K | $225.00K | $225.00K | $275.19K |
| High Forecast | $3.53M | $3.34M | $3.24M | $1.02M | $4.56M | $4.48M | $3.80M | $3.57M | $2.08M | $3.85M | $2.67M | $5.74M | $305.59K | $513.50K | $1.13M | $3.05M | $1.14M | $2.40M | $1.06M | $585.60K | $1.49M | $1.27M | $930.00K | $1.36M | $836.00K | $225.00K | $225.00K | $225.00K | $330.23K |
| Low Forecast | $327.27K | $309.09K | $300.00K | $511.11K | $300.16K | $414.41K | $351.55K | $330.16K | $68.56K | $356.59K | $247.50K | $531.82K | $28.30K | $513.50K | $1.13M | $3.05M | $1.14M | $2.40M | $1.06M | $585.60K | $1.49M | $1.27M | $930.00K | $1.36M | $836.00K | $225.00K | $225.00K | $225.00K | $220.15K |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.52% | 0.10% | 1.46% | 0.13% | 0.02% | 0.33% | 1.38% | 1.00% | 2.59% | 2.65% | 0.32% | 0.55% | 1.16% | 0.66% | 1.26% | 4.37% | 4.69% | 1.64% | 1.63% |
Cue Biopharma's average Quarter revenue forecast for Sep 23 based on 2 analysts is $1.31M, with a low forecast of $356.59K, and a high forecast of $3.85M. CUE's average Quarter revenue forecast represents a -5.39% decrease compared to the company's last Quarter revenue of $1.38M (Jun 23).
Cue Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-12.10M | $-11.86M | $-13.67M | $-10.29M | $-12.88M | $-13.93M | $-7.58M | $-12.68M | $-9.96M | $-12.19M | $-10.64M | $-9.76M | $-11.56M | $-11.56M | $-7.39M | $-5.77M | $-7.89M | $-10.06M | $-12.37M |
| Avg Forecast | $-1.20M | $-1.13M | $-1.10M | $-766.67K | $-1.43M | $-1.52M | $-1.29M | $-1.21M | $-966.67K | $-1.31M | $-907.50K | $-1.95M | $-103.75K | $-513.50K | $-1.13M | $-13.60M | $-1.14M | $-2.40M | $-1.06M | $-11.22M | $-1.49M | $-1.27M | $-930.00K | $-7.26M | $-836.00K | $-225.00K | $-225.00K | $-6.54M | $-5.01M |
| High Forecast | $-327.27K | $-309.09K | $-300.00K | $-511.11K | $-300.16K | $-414.41K | $-351.55K | $-330.16K | $-68.56K | $-356.59K | $-247.50K | $-531.82K | $-28.30K | $-513.50K | $-1.13M | $-10.88M | $-1.14M | $-2.40M | $-1.06M | $-8.98M | $-1.49M | $-1.27M | $-930.00K | $-5.81M | $-836.00K | $-225.00K | $-225.00K | $-5.23M | $-4.01M |
| Low Forecast | $-3.53M | $-3.34M | $-3.24M | $-1.02M | $-4.56M | $-4.48M | $-3.80M | $-3.57M | $-2.08M | $-3.85M | $-2.67M | $-5.74M | $-305.59K | $-513.50K | $-1.13M | $-16.32M | $-1.14M | $-2.40M | $-1.06M | $-13.47M | $-1.49M | $-1.27M | $-930.00K | $-8.72M | $-836.00K | $-225.00K | $-225.00K | $-7.85M | $-6.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 13.34% | 6.08% | 131.78% | 20.04% | 11.38% | 1.02% | 6.65% | 5.29% | 9.43% | 1.09% | 7.15% | 7.68% | 12.43% | 1.59% | 8.84% | 25.65% | 35.08% | 1.54% | 2.47% |
undefined analysts predict CUE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cue Biopharma's previous annual EBITDA (undefined) of $NaN.
Cue Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-13.19M | $-13.21M | $-14.45M | $-10.88M | $-13.33M | $-14.27M | $-8.39M | $-12.99M | $-10.28M | $-12.51M | $-11.10M | $-10.03M | $-10.83M | $-12.82M | $-8.92M | $-6.99M | $-9.52M | $-11.27M | $-12.56M |
| Avg Forecast | $-7.00M | $-6.83M | $-6.83M | $-7.68M | $-5.74M | $-9.35M | $-14.34M | $-14.45M | $-15.37M | $-16.65M | $-15.63M | $-14.22M | $-15.11M | $-18.90M | $-19.57M | $-13.92M | $-21.17M | $-19.32M | $-20.92M | $-11.52M | $-17.56M | $-18.26M | $-20.32M | $-8.06M | $-22.45M | $-22.08M | $-23.08M | $-7.32M | $-5.09M |
| High Forecast | $-381.90K | $-372.57K | $-372.57K | $-6.66M | $1.08M | $-509.97K | $-782.42K | $-788.01K | $-13.78M | $-908.16K | $-852.27K | $-775.43K | $-824.33K | $-18.90M | $-19.57M | $-11.14M | $-21.17M | $-19.32M | $-20.92M | $-9.21M | $-17.56M | $-18.26M | $-20.32M | $-6.45M | $-22.45M | $-22.08M | $-23.08M | $-5.86M | $-4.07M |
| Low Forecast | $-24.71M | $-24.11M | $-24.11M | $-8.71M | $-10.76M | $-33.00M | $-50.62M | $-50.98M | $-18.02M | $-58.76M | $-55.14M | $-50.17M | $-53.33M | $-18.90M | $-19.57M | $-16.71M | $-21.17M | $-19.32M | $-20.92M | $-13.82M | $-17.56M | $-18.26M | $-20.32M | $-9.67M | $-22.45M | $-22.08M | $-23.08M | $-8.79M | $-6.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.84% | 0.93% | 0.96% | 0.58% | 0.68% | 1.03% | 0.40% | 0.67% | 0.49% | 1.09% | 0.63% | 0.55% | 0.53% | 1.59% | 0.40% | 0.32% | 0.41% | 1.54% | 2.47% |
Cue Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CUE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cue Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $4.25M | $4.18M | $3.70M | $3.53M | $3.78M | $5.16M | $4.67M | $4.10M | $4.28M | $4.25M | $3.45M | $3.32M | $3.90M | $3.99M | $3.10M | $2.78M | $3.42M | $3.44M | $2.90M |
| Avg Forecast | $6.12M | $5.78M | $5.61M | $3.91M | $7.27M | $7.75M | $6.58M | $6.18M | $4.93M | $6.67M | $4.63M | $9.95M | $529.33K | $2.57M | $5.65M | $15.26M | $5.69M | $11.97M | $5.28M | $2.93M | $7.44M | $6.35M | $4.65M | $6.78M | $4.18M | $1.12M | $1.12M | $1.12M | $1.37M |
| High Forecast | $18.03M | $17.03M | $16.53M | $5.22M | $23.28M | $22.83M | $19.37M | $18.19M | $10.60M | $19.65M | $13.64M | $29.30M | $1.56M | $2.57M | $5.65M | $15.26M | $5.69M | $11.97M | $5.28M | $2.93M | $7.44M | $6.35M | $4.65M | $6.78M | $4.18M | $1.12M | $1.12M | $1.12M | $1.65M |
| Low Forecast | $1.67M | $1.58M | $1.53M | $2.61M | $1.53M | $2.11M | $1.79M | $1.68M | $349.78K | $1.82M | $1.26M | $2.71M | $144.36K | $2.57M | $5.65M | $15.26M | $5.69M | $11.97M | $5.28M | $2.93M | $7.44M | $6.35M | $4.65M | $6.78M | $4.18M | $1.12M | $1.12M | $1.12M | $1.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.42% | 7.00% | 1.38% | 0.67% | 0.34% | 0.82% | 0.34% | 0.81% | 1.45% | 0.46% | 0.52% | 0.84% | 0.59% | 0.74% | 2.47% | 3.04% | 3.06% | 2.11% |
Cue Biopharma's average Quarter SG&A projection for Sep 23 is $6.67M, based on 2 Wall Street analysts, with a range of $1.82M to $19.65M. The forecast indicates a 57.00% rise compared to CUE last annual SG&A of $4.25M (Jun 23).
Cue Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.29 | $-0.30 | $-0.41 | $-0.31 | $-0.38 | $-0.44 | $-0.27 | $-0.41 | $-0.33 | $-0.41 | $-0.37 | $-0.34 | $-0.38 | $-0.48 | $-0.37 | $-0.31 | $-0.46 | $-0.54 | $-0.62 |
| Avg Forecast | $-0.14 | $-0.13 | $-0.13 | $-0.15 | $-0.11 | $-0.18 | $-0.28 | $-0.28 | $-0.30 | $-0.33 | $-0.30 | $-0.28 | $-0.29 | $-0.38 | $-0.39 | $-0.40 | $-0.42 | $-0.39 | $-0.42 | $-0.38 | $-0.35 | $-0.36 | $-0.41 | $-0.33 | $-0.45 | $-0.44 | $-0.46 | $-0.40 | $-0.15 |
| High Forecast | $-0.01 | $-0.01 | $-0.01 | $-0.13 | $0.02 | $-0.01 | $-0.02 | $-0.02 | $-0.27 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.38 | $-0.39 | $-0.40 | $-0.42 | $-0.39 | $-0.42 | $-0.38 | $-0.35 | $-0.36 | $-0.41 | $-0.33 | $-0.45 | $-0.44 | $-0.46 | $-0.40 | $-0.12 |
| Low Forecast | $-0.48 | $-0.47 | $-0.47 | $-0.17 | $-0.21 | $-0.64 | $-0.99 | $-1.00 | $-0.35 | $-1.15 | $-1.08 | $-0.98 | $-1.04 | $-0.38 | $-0.39 | $-0.40 | $-0.42 | $-0.39 | $-0.42 | $-0.38 | $-0.35 | $-0.36 | $-0.41 | $-0.33 | $-0.45 | $-0.44 | $-0.46 | $-0.40 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.08% | 1.39% | 0.82% | 0.97% | 1.09% | 0.64% | 1.06% | 0.79% | 1.08% | 1.07% | 0.93% | 0.94% | 1.44% | 0.83% | 0.70% | 1.00% | 1.35% | 4.13% |
According to undefined Wall Street analysts, Cue Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CUE previous annual EPS of $NaN (undefined).
Cue Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.33 | $14.00 | 4142.42% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| DRMA | Dermata Therapeutics | $1.08 | $6.00 | 455.56% | Buy |
| INMB | INmune Bio | $4.87 | $22.00 | 351.75% | Buy |
| CUE | Cue Biopharma | $1.10 | $4.33 | 293.64% | Buy |
| FENC | Fennec Pharmaceuticals | $4.04 | $15.75 | 289.85% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.01 | $38.80 | 198.23% | Buy |
| COYA | Coya Therapeutics | $6.07 | $18.00 | 196.54% | Buy |
| PYPD | PolyPid | $3.46 | $10.00 | 189.02% | Buy |
| TCRX | TScan Therapeutics | $4.20 | $12.00 | 185.71% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| TERN | Terns Pharmaceuticals | $5.70 | $14.25 | 150.00% | Buy |
| ANIX | Anixa Biosciences | $3.05 | $7.50 | 145.90% | Buy |
| HOOK | HOOKIPA Pharma | $2.80 | $3.00 | 7.14% | Buy |